Candesartan-Associated Lichenoid Drug Eruption

Lichenoid drug eruption (LDE) is an uncommon adverse drug reaction, with few published cases implicating the angiotensin II receptor blocker candesartan. We report a 67-year-old woman who developed pruritic violaceous papules and plaques on the trunk and extremities two years after initiating candesartan. Skin biopsy confirmed LDE. The eruption gradually resolved over five to six months after candesartan was replaced by amlodipine, with no recurrence observed at the 12-month follow-up. This case underscores the diagnostic challenges associated with LDE: latency may extend over years, clinical and histopathologic features closely mimic idiopathic lichen planus, and confirmatory tests, such as patch testing and drug-induced lymphocyte stimulation testing, often yield low sensitivity. Dermatologists and prescribing physicians should maintain a high index of suspicion for drug-induced lichenoid reactions, even when no recent medication changes are reported, as prompt recognition and withdrawal of the offending agent are essential for achieving durable remission.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-06-13
DOI
https://doi.org/10.7759/cureus.85920
Primary Topic
Oral Health Pathology and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Candesartan-Associated Lichenoid Drug Eruption

Kazuyoshi Iijima, Yoshihito Mima
Cureus
Oral Health Pathology and Treatment
article

Candesartan-Associated Lichenoid Drug Eruption

Kazuyoshi Iijima, Yoshihito Mima
article en

Abstract

Lichenoid drug eruption (LDE) is an uncommon adverse drug reaction, with few published cases implicating the angiotensin II receptor blocker candesartan. We report a 67-year-old woman who developed pruritic violaceous papules and plaques on the trunk and extremities two years after initiating candesartan. Skin biopsy confirmed LDE. The eruption gradually resolved over five to six months after candesartan was replaced by amlodipine, with no recurrence observed at the 12-month follow-up. This case underscores the diagnostic challenges associated with LDE: latency may extend over years, clinical and histopathologic features closely mimic idiopathic lichen planus, and confirmatory tests, such as patch testing and drug-induced lymphocyte stimulation testing, often yield low sensitivity. Dermatologists and prescribing physicians should maintain a high index of suspicion for drug-induced lichenoid reactions, even when no recent medication changes are reported, as prompt recognition and withdrawal of the offending agent are essential for achieving durable remission.

CureusVol. 17(6)
Tokyo Metropolitan Police Hospital (JP), Teikyo University (JP)
Openalex Percentile: Top 85%
Oral Health Pathology and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Candesartan-Associated Lichenoid Drug Eruption — Kazuyoshi Iijima, Yoshihito Mima · Cureus (2025) | TGRS Research Map | TGRS